Business Standard

Sun Pharma to test two drugs for treatment of Covid-19, stock up 3.5%

At present there are three clinical trials underway to test nafamostat in Covid19 patients around the world

Sun Pharma
Premium

Nafamostat is currently not sold in India

Sohini Das Mumbai
India’s largest drug maker Sun Pharmaceutical Industries is readying to start trials on a few drugs that have emerged as potential treatment candidates for Covid-19. This includes an anti-coagulant and anti-inflammatory drug nafamostat and another plant-based dengue drug candidate that Sun Pharma was developing along with government research institutes. 

The development comes at a time when several Indian companies are lining up testing of potential drug candidates on Covid-19 patients. Mumbai-based Glenmark, too, has started trials on favipiravir, an influenza drug that has shown some promise.

On Friday, Sun Pharma said it received the nod from the Drug Controller General of India

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 29 2020 | 7:25 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com